<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_maraviroc.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:51 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Maraviroc</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Maureen M. Forrestel, Pharm.D. and Paul A. Pham, Pharm.D. </author>
<br>
<span class="display_date">04-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Currently not available in Zambia. </li>
<li>Active against NRTI-, NNRTI-, and PI-resistant strains, but patients must tested for R5-tropism before MVC use (cost of tropism assay (Trofile)&nbsp;approx. $2000, and not available in Zambia)&nbsp; </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Used in combination with other antiretroviral agents in treatment-experienced adult patients infected with CCR5 (R5)-tropic HIV-1. </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">Selzentry (U.S); Celsentri (Europe)</TD><TD valign="top">Maraviroc (MVC)</TD><TD valign="top">Pfizer</TD><TD>oral</TD><TD>tablet</TD><TD>150 mg and 300 mg </TD><TD>Approx. $900/month</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>
<ul>
<li>MVC 300 mg PO bid with or without food </li>
<li>With PIs (except TPV/r) : MVC 150 mg PO bid. (use standard dose with TPV/r)</li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: MVC 150 mg PO bid</li>
<li>With SQV/r + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: MVC 150 mg PO bid</li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: MVC 600 mg PO bid</li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: no data, consider MVC 300 mg PO bid</li>
<li>With <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: MVC 150 mg PO bid</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose likely. Dose post-HD on days of dialysis. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>Usual dose likely. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">GENERAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>MVC generally well tolerated in clinical trials, with similar rates of study discontinuation vs. placebo. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Diarrhea, nausea, headache and fatigue,&nbsp;that occurred at rates similar to or less than those of placebo. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Cough, fever and upper respiratory tract infection (pneumonia was uncommon)</li>
<li>Rash</li>
<li>AST/ALT elevation </li>
<li>CK elevation</li>
<li>Myalgia</li>
<li>Abdominal pain</li>
<li>Dizziness </li>
<li>Orthostatic hypotension (dose dependent, uncommon at the recommended dose)</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity0e98.html?contentInstanceId=434823">Hepatotoxicity</A> with allergic features (rash, eosinophilia, elevated IgE) </li>
<li>Cardiac events related to coronary artery disease (1.3%)</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>MVC does not inhibit or induce CYP3A4. As MVC is a substrate of CYP 3A4 and P-gp, the dose should be adjusted when co-administered with CYP3A4 and/or P-gp inhibitors or inducers. Drug-drug interactions are unlikely with NRTIs and <A class="headLines" target="_new" href="enfuvirtide5d38.html?contentInstanceId=443127">enfuvirtide</A>.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">Nevirapine</A>&nbsp;<BR>
<BR>
</B></TD><TD valign="top">MVC serum concentration was not significantly affected compared to historical controls in a single dose study; however, MVC AUC may be decreased at steady state. </TD><TD valign="top">Dose: MVC 300 mg bid + standard dose <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz</A>
          </B></TD><TD valign="top">MVC AUC decreased by 45%. </TD><TD valign="top">Increase MVC to 600 mg bid with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir</A>
          </B></TD><TD valign="top">MVC AUC increased 257% </TD><TD valign="top">Decrease MVC to 150 mg bid with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir</A>
          </B></TD><TD valign="top">No significant interaction</TD><TD valign="top">Use standard doses. MVC 300 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">Delavirdine</A>
          </B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">Erythromycin</A>
          </B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A></B></TD><TD valign="top">MVC AUC increased 732% </TD><TD valign="top">Decrease MVCto 150 mg bid with SQV/r co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">Lopinavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A></B></TD><TD valign="top">MVC AUC increased 283% </TD><TD valign="top">Decrease MVCto 150 mg bid with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A></B></TD><TD valign="top">MVC AUC increased 388% </TD><TD valign="top">Decrease MVC to 150 mg bid with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>/r co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A></B></TD><TD valign="top">No significant interaction</TD><TD valign="top">Use standard doses. MVC 300 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">Lopinavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">efavirenz</A>
<BR>
</B></TD><TD valign="top">MVC AUC increased 153% </TD><TD valign="top">Decrease MVC to 150 mg bid with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>+<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">Saquinavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A> + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">efavirenz</A></B></TD><TD valign="top">MVC AUC increased 400% </TD><TD valign="top">Decrease MVC to 150 mg bid with SQV/r+<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B><A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">ritonavir</A></B></TD><TD valign="top">MVC AUC increased 344% with co-administration.</TD><TD valign="top">Decrease MVC to 150 mg bid with DRV/r co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Carbamezapine</B></TD><TD valign="top">MVC AUC may significantly decrease with carbamezapine co-administration. </TD><TD valign="top">Increase MVC to 600 mg bid with co-administration, or consider alternative anticonvulsant (i.e valproic acid or levetiracetam).</TD>
</TR>
<TR>
<TD valign="top"><B>Clarithromycin&nbsp;<BR>
</B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinylestradiol </B></TD><TD valign="top">No significant interaction </TD><TD valign="top">Use standard doses. Consider an additional barrier form of contraception. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>Ketoconazole&nbsp;<BR>
</B></TD><TD valign="top">MVC AUC increased 5-fold with co-administration.</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>Levonorgestrel </B></TD><TD valign="top">No significant interaction </TD><TD valign="top">Use standard doses. Consider an additional barrier form of contraception.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Midazolam
          </B></TD><TD valign="top">Midazolam AUC increased by 18%. </TD><TD valign="top">Unlikely to be clinically significant.Use standard doses. </TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital<BR>
</B></TD><TD valign="top">MVC AUC may significantly decrease with phenobarbital co-administration. </TD><TD valign="top">Increase MVC to 600 mg bid with co-administration, or consider alternative anticonvulsant (i.e valproic acid or levetiracetam).</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin </B></TD><TD valign="top">MVC AUC may significantly decrease with phenytoin co-administration. </TD><TD valign="top">Increase MVC dose to 600 mg bid with co-administration, or consider alternative anticonvulsant (i.e valproic acid or levetiracetam).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">May decrease MVC serum concentrations</TD><TD valign="top">Increase MVC to 600 mg bid with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Rifampin&nbsp;<BR>
</B></TD><TD valign="top">MVC AUC decreased 66% with co-administration.</TD><TD valign="top">Increase MVC to 600 mg bid with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Sulfamethoxazole-<A class="headLines" target="_new" href="../antimicrobial_agents/trimethoprimd0d4.html?contentInstanceId=434152">trimethoprim</A></B></TD><TD valign="top">MVC AUC increased 10% </TD><TD valign="top">Use standard dose. MVC 300 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Telithromycin
          </B></TD><TD valign="top">May increase MVC serum concentrations</TD><TD valign="top">Dose: MVC 150 mg bid.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>MVC-resistant viruses that emerged <I>in vitro </I>contained amino acid substitutions/deletions in the V3 loop of the HIV-1 envelope (gp120), with the primary substitutions isolated being A19T and I26V. MVC failure can also be due to a tropism shift, leading to the emergence of X4 or dual/mixed-tropic virus that is not inhibited by MVC. Tropism shifts probably represent selection of pre-existing minority variants rather than true shift of R5-tropic virus.</li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10A5B"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>MVC inhibits CCR5 receptors on the cell membrane, preventing the interaction of gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Rapid absorption with a 33% bioavailability.</li>
<li>Metabolism and Excretion: 
                22% metabolized by CYP3A4 (N-dealkylation) and 11% hydroxylated. Both inactive metabolites and unchanged drugs are excreted via fecal route (&gt;76%). </li>
<li>Protein Binding: 
                76%</li>
<li>Cmax, Cmin, and AUC: 
                Cmax=266 ng/mL; Cmin=54 ng/mL; AUC=1681 ng h/mL</li>
<li>T1/2: 
                14-18 hrs.</li>
<li>Distribution: 
                194 L</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Limited data; no dose adjustment likely. A single-dose study in subjects with mild to moderate hepatic impairment has shown little impact on MVC pharmacokinetics, with less than a 50% increase in exposure to MVC. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B: No human data. Not teratogenic in rats or rabbits studies. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>Based on animal studies, MVC is extensively secreted into rat milk. MVC is not recommended in breast feeding mothers. <a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>MVC is the first&nbsp;CCR antagonist. There is no cross-resistance to currently available drugs. MVC was effective when used in combination with OBT in heavily treatment-experienced pats with R5-tropic virus and multiple resistance mutations who were failing therapy. Use of MVC in these pts resulted in a mean VL reduction of almost 2 logs andVL suppression to &lt;/-50 in 45% of treated pts. <br>
<br>
<ul>
<li>MVC not recommended in pts with dual/mixed (D/M)- or X4-tropic virus due to lack of efficacy.</li>
<li>Tropism assay should be performed prior to initiation of treatment with MVC. The Trofile&trade; (Monogram Biosciences, Inc.) co-receptor tropism assay is the only commercially available assay; it detectspresence of R5-, X4-, or dual/mixed-tropic virus.</li>
<li>Tropism assay requires VL &gt;1000, which means that MVC cannot be used to substitute for other drugs in a suppressive regimen.</li>
<li>Sensitivity of tropism assay to detect D/M or X4-tropic virus is 100% when it comprises at least 10% of total viral population, and 83%when it comprises at least 5% of population. In MOTIVATE trials 7.6% of participants had R5-tropic virus at screening but had D/M-tropic virus at baseline (4-6 wks later), presumably representing failure of initial assay to detect D/M- or X4-tropic virus present at low levels. </li>
<li>Samples can be sent to Monogram Biosciences for processing, either directly or by the processing laboratory. Practitioners should contact Monogram Biosciences, Inc. for further information on sample processing and reimbursement (<A class="headLines" target="_new" href="http://www.trofileassay.com/">http://www.trofileassay.com</A>). </li>
<li>Although MVC clearly has a role in the management of treatment-experienced pts, the lack of long-term safety data, non-viral target, high cost of the tropism assay, inconvenience of bid dosing, and failure to meet non-inferiority threshold compared to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> for &lt;50 threshold in the MERIT trial MVC is unlikely be used in treatment-naive pts in the near future.</li>
</ul>
<a name="N10AB2"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Saag M, Ive P, Heera J, et al. ;
		A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc, versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral-naive patients infected with R5 HIV1: Week 48 results of the MERIT study ;        
		
            <A class="headLines" target="_new" href="http://www.ias2007.org/pag/Abstracts.aspx?AID=5558">4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007. Abstract WESS104</A>
          ;
		2007; Vol. 
		<br>
<b>Comments:</b>Over 700 pts with mean baseline VL4.8 logs and med. CD4 of approximately 250 were enrolled in this prospective randomized trial. Study participants received AZT/3TC&nbsp;with either <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> or MVC for 48 wks. MVC (dosed bid) was found to be non-inferior to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> in viral suppression to &lt;/-400 (70.6% vs. 73.1%, respectively), but MVC did not meet non-inferiority threshold using &lt;/-50 assay (65.3% vs. 69.3%). Pts with baseline VL&gt; 100,000 were less likely to achieve a VL&lt;?50 with MVC than <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> (59.6% vs. 66.6%), although suppression was similar in those with VL &lt;100,000(69.6% vs. 71.6%). Pts from the study sites in the Southern hemisphere, comprising almost half the study population, were less likely to achieve viral suppression to &lt;50 with MVC (62.1%) compared to <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> (71.0%), whereas this difference was not observed in pts from Northern hemisphere sites (68.0% vs. 67.8%). Mean CD4 increases were 170 and 144 in the MVC- and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-treated pts, respectively. Overall discontinuation rates were similar between groups; however, pts on MVC were less likely than pts on <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> to withdraw from the study due to AEs (4.2% vs. 13.6%, respectively), but more likely to withdraw due to lack of treatment effect (11.9% vs. 4.2%, respectively). CNS side effects more common in the <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-treated group. <br>
<br>
</li>
<li>Lalezari J, Goodrich J, DeJesus E, et al. ;
		Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results from a phase 2b/3 study in the US and Canada. ;        
		
            <A class="headLines" target="_new" href="http://www.retroconference.org/2007/Abstracts/30635.htm">14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 104bLB, 27thFebruary, 2007</A>
          ;
		2007; Vol. 
		<br>
<b>Comments:</b>Heavily treatment-experienced pts who were failing their current ARV regimens, had at least 6 mos of prior treatment with at least 1 agent (2 agents for PIs) from 3 of 4 ARV drug classes, and/or documented resistance to 3 of the 4 ARV drug classes and VL &gt;5000 were enrolled. Pts enrolled had a med.VL of 4.86 log and med. CD4 of 167. 41%? had baseline VL<U>&gt;</U>100,000 and 58% had a baseline CD4 &lt;200. Approximately 2/3 had an overall susceptibility score (OSS, the number of active drugs in the background regimen) of &lt;3. The wk 24 ITT analysis in both studies demonstrated significantly greater reduction of VL from baseline in both MVC arms vs. placebo. Mean change in VL was -1.87, -1.96, and -0.99 login qd, bid, and placebo treated groups, respectively. VL suppression to &lt;50 achieved in 44.0%, 45.3%, and 23.0% of respective groups. When stratified for ENF use in ENF-naive pts, mean VL reductions was significantly higher in ENF treated pts who had not previously used ENF [<A class="headLines" target="_new" href="http://www.iasociety.org/Default.aspx?pageId=11&amp;abstractId=200705513">van der Ryst E, et al. 4th IAS Conference, Sydney, 2007, Abstract WEPEB115LB</A>]. As expected, virologic response was better ifOBR contained active drugs. VL&lt;50 achieved in 32.7%, 46.7%, 55.7%, and 59% of MVC-treated pts when they had 0, 1, 2, 3 active drugs in the OBR, respectively. <br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_maraviroc.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:51 GMT -->
</html>
